Uso da gelatina fibrilar para hemostasia na neurocirurgia pediátrica

• Ano de defesa: 2025
• Autor(a) principal: Colodetti, Rafael
• Orientador(a): Gouvea, Sônia Alves
• Banca de defesa: Kusahara, Denise Miyuki , Bezerra, Itala Maria Pinheiro , Paula, Flavia de
• Tipo de documento: Tese
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Espírito Santo; Doutorado em Biotecnologia
• Programa de Pós-Graduação: Programa de Pós-Graduação em Biotecnologia
• Departamento: Centro de Ciências da Saúde
• País: BR
• Palavras-chave em Português: Hemostasia; Hemostasia cirúrgica; Neurocirurgia; Pediatria; Hemostasis surgical hemostasis; Neurosurgery; Pediatrics
• Área do conhecimento CNPq: Biotecnologia
• Link de acesso: http://repositorio.ufes.br/handle/10/20475

Introduction: Pediatric neurosurgery has peculiarities in that it treats patients with a variety of sizes and physical development, covering diseases that are sometimes non-existent among adults. These characteristics make them more susceptible to surgical complications due to low tolerance to bleeding. Therefore, the use of topical hemostatics is suitable for rapid control of hemorrhages in all surgical periods. Objective: To evaluate the feasibility, performance and safety of fibrillar gelatin-based hemostatic (HBGF) in pediatric neurosurgery. Material and Methods: The selection of the sample group was random, intentional and non-probabilistic. The performance assessment of the HBGF was carried out by applying a performance questionnaire containing a classification into 5 topics (excellent, good, satisfactory, moderate and poor), focusing on its characteristics in stopping bleeding, absorption capacity, general handling, adherence to the lesion and ease of repositioning. Clinical and neuroimaging parameters were monitored 24 hours and 30 to 60 days after the surgical approach. Appropriate statistical tests were used to analyze the data. Results: The sample was divided into 4 groups, with Group 1 (G1) open surgeries for brain tumor resection; Group 2 (G2) open surgeries, no brain tumor; Group 3 (G3) minimally invasive procedures; and, Group 4 (G4), tumors in the posterior fossa. The highest prevalence was between 2 and 5 years old, in girls and with total biodegradation of HBGF within 8 weeks. In all groups, the majority had a hemostasis time of “gelatin-based hemostatic in fibrillar presentation. This demonstrated feasibility, good performance and safety in several pediatric neurosurgery procedures.